Ethinylestradiol/levonorgestrel (ascending/constant dose) - Teva

Drug Profile

Ethinylestradiol/levonorgestrel (ascending/constant dose) - Teva

Alternative Names: DR 1031; DR-0131; Levonorgestrel/ethinyl estradiol and ethinyl estradiol; Levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets; Quartette

Latest Information Update: 06 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Alkylated estrogenic steroids; Contraceptives; Hormonal replacements; Norpregnanes; Norpregnatrienes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 10 Feb 2014 Teva has patent protection for ethinylestradiol/levonorgestrel (ascending/constant dose) in USA
  • 24 Sep 2013 Launched for Contraception/Pregnancy (Prevention) in USA (PO) - First global launch
  • 29 Mar 2013 Registered for Contraception/Pregnancy (Prevention) in USA (PO) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top